Crossmark

Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy

Crossref DOI link: https://doi.org/10.1186/s13045-020-00896-0

Published Online: 2020-06-09

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Basher, Fahmin

Dhar, Payal

Wang, Xin

Wainwright, Derek A.

Zhang, Bin

Sosman, Jeffrey

Ji, Zhe

Wu, Jennifer D.
Funding

Funding for this research was provided by:

National Institutes of Health (1R01CA208246, 1R01CA204021)
License Information

Text and Data Mining valid from 2020-06-09

Version of Record valid from 2020-06-09
More Information

Article History

Received: 2 March 2020

Accepted: 8 May 2020

First Online: 9 June 2020

Ethics approval and consent to participate

: All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of the Medical University of South Carolina and the IACUC committee of Northwestern University. Human TMAs were purchased from the commercial vendor, US BIOMAX.

: Not applicable.

: J. Wu is the inventor of the B10G5 antibody and has international patent applications. All other authors declare no conflict of interest.

Document is current

Any future updates will be listed below